复发转移性鼻咽癌的综合治疗进展
Advances in Comprehensive Treatment of Recurrent and Metastatic Nasopharyngeal Carcinoma
DOI: 10.12677/acm.2025.15102789, PDF,   
作者: 周 艳：吉首大学医学院，湖南 吉首；熊 莉*：吉首大学第一附属医院肿瘤科(湘西自治州人民医院)，湖南 吉首
关键词: 鼻咽癌；放化疗；靶向治疗；免疫治疗；局部治疗；维持治疗；Nasopharyngeal Carcinoma； Chemoradiotherapy； Targeted Therapy； Immunotherapy； Local Therapy； Maintenance Therapy
摘要: 鼻咽癌是有着明显地域性的恶性头颈部肿瘤，主要分布于中国两广地区，广东和广西。远处转移和局部复发是鼻咽癌治疗失败的主要原因，早期鼻咽癌主要以根治性放疗治疗为主，而晚期主要以综合治疗为主，着重于个体化治疗。近年来，随着免疫治疗及靶向治疗取得了突破性成就，晚期鼻咽癌的治疗方案也有所变化。本文就同步放化疗，免疫治疗，靶向治疗，局部治疗，维持治疗五方面进行简要概述。
Abstract: Nasopharyngeal carcinoma (NPC) is a highly regional malignant head and neck tumor, predominantly endemic to Guangdong and Guangxi provinces in southern China. Distant metastasis and locoregional relapse remain the principal causes of treatment failure. Early-stage NPC is managed primarily with radical radiotherapy, whereas advanced disease is treated with comprehensive treatment, focusing on the individualized therapy. Recent breakthroughs in immunotherapy and targeted agents have reshaped therapeutic strategies for late-stage NPC. This review provides a concise update on five key modalities: concurrent chemoradiotherapy, immunotherapy, targeted therapy, locoregional treatment, and maintenance therapy.
文章引用：周艳, 熊莉. 复发转移性鼻咽癌的综合治疗进展[J]. 临床医学进展, 2025, 15(10): 550-554. https://doi.org/10.12677/acm.2025.15102789

参考文献

[1] Lee, A.W., Ng, W.T., Pan, J.J., Chiang, C., Poh, S.S., Choi, H.C., et al. (2019) International Guideline on Dose Prioritization and Acceptance Criteria in Radiation Therapy Planning for Nasopharyngeal Carcinoma. International Journal of Radiation Oncology Biology Physics, 105, 567-580. [Google Scholar] [CrossRef] [PubMed]
[2] 梁忠国, 朱小东. 鼻咽癌放疗技术与靶区的研究进展[J]. 中国癌症防治杂志, 2021, 13(3): 316-320.
[3] Zheng, S., Liu, S., Wang, H., Wei, Y., Li, H., Wang, G., et al. (2021) Treatment and Survival Outcomes Associated with Platinum Plus Low-Dose, Long-Term Fluorouracil for Metastatic Nasopharyngeal Carcinoma. JAMA Network Open, 4, e2138444. [Google Scholar] [CrossRef] [PubMed]
[4] Hu, J., Huang, Q., Gao, J., Guan, X., Hu, W., Yang, J., et al. (2020) Clinical Outcomes of Carbon‐Ion Radiotherapy for Patients with Locoregionally Recurrent Nasopharyngeal Carcinoma. Cancer, 126, 5173-5183. [Google Scholar] [CrossRef] [PubMed]
[5] 张溪夏, 曹志伟. PD-1PD-L1单抗在复发转移性鼻咽癌中的研究进展[J]. 中国肿瘤临床, 2020, 47(23): 1231-1235.
[6] Zhang, L., Huang, Y., Hong, S., Yang, Y., Yu, G., Jia, J., et al. (2016) Gemcitabine Plus Cisplatin versus Fluorouracil Plus Cisplatin in Recurrent or Metastatic Nasopharyngeal Carcinoma: A Multicentre, Randomised, Open-Label, Phase 3 Trial. The Lancet, 388, 1883-1892. [Google Scholar] [CrossRef] [PubMed]
[7] Hong, S., Zhang, Y., Yu, G., Peng, P., Peng, J., Jia, J., et al. (2021) Gemcitabine Plus Cisplatin versus Fluorouracil Plus Cisplatin as First-Line Therapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: Final Overall Survival Analysis of GEM20110714 Phase III Study. Journal of Clinical Oncology, 39, 3273-3282. [Google Scholar] [CrossRef] [PubMed]
[8] Li, W., Duan, X., Chen, X., Zhan, M., Peng, H., Meng, Y., et al. (2023) Immunotherapeutic Approaches in EBV-Associated Nasopharyngeal Carcinoma. Frontiers in Immunology, 13, Article 1079515. [Google Scholar] [CrossRef] [PubMed]
[9] Guo, L., Lu, G., Lu, Z., Yu, Y. and Wu, S. (2025) Patterns of Failure and Prognosis in Nasopharyngeal Carcinoma According to Epstein-Barr Virus DNA Status. Infectious Agents and Cancer, 20, Article No. 6. [Google Scholar] [CrossRef] [PubMed]
[10] Yang, Y., Qu, S., Li, J., Hu, C., Xu, M., Li, W., et al. (2021) Camrelizumab versus Placebo in Combination with Gemcitabine and Cisplatin as First-Line Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (Captain-1st): A Multicentre, Randomised, Double-Blind, Phase 3 Trial. The Lancet Oncology, 22, 1162-1174. [Google Scholar] [CrossRef] [PubMed]
[11] Tan, L.L.Y., Le, Q., Lee, N.Y.Y. and Chua, M.L.K. (2021) JUPITER‐02 Trial: Advancing Survival for Recurrent Metastatic Nasopharyngeal Carcinoma and Next Steps. Cancer Communications, 42, 56-59. [Google Scholar] [CrossRef] [PubMed]
[12] Yang, Y., Pan, J., Wang, H., Zhao, Y., Qu, S., Chen, N., et al. (2023) Tislelizumab Plus Chemotherapy as First-Line Treatment for Recurrent or Metastatic Nasopharyngeal Cancer: A Multicenter Phase 3 Trial (Rationale-309). Cancer Cell, 41, 1061-1072.e4. [Google Scholar] [CrossRef] [PubMed]
[13] Chan, A.T.C., Lee, V.H.F., Hong, R.-L., Ahn, M.-J., Chong, W.Q., Kim, S., et al. (2023) Pembrolizumab Monotherapy versus Chemotherapy in Platinum-Pretreated, Recurrent or Metastatic Nasopharyngeal Cancer (KEYNOTE-122): An Open-Label, Randomized, Phase III Trial. Annals of Oncology, 34, 251-261. [Google Scholar] [CrossRef] [PubMed]
[14] Jung, H.A., Park, K., Cho, S., Lim, J., Lee, K., Hong, M.H., et al. (2022) A Phase II Study of Nivolumab Plus Gemcitabine in Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma (KCSG Hn17-11). Clinical Cancer Research, 28, 4240-4247. [Google Scholar] [CrossRef] [PubMed]
[15] Lim, D.W., Kao, H., Suteja, L., Li, C.H., Quah, H.S., Tan, D.S., et al. (2023) Clinical Efficacy and Biomarker Analysis of Dual PD-1/CTLA-4 Blockade in Recurrent/Metastatic EBV-Associated Nasopharyngeal Carcinoma. Nature Communications, 14, Article No. 2781. [Google Scholar] [CrossRef] [PubMed]
[16] Xue, S., Song, G., Zhu, Y., Zhang, N. and Tan, Y. (2022) The Efficacy and Safety of VEGF/VEGFR Inhibitors in Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma: A Meta-Analysis. Oral Oncology, 135, Article ID: 106231. [Google Scholar] [CrossRef] [PubMed]
[17] Chen, C., Zhang, X., Zhou, Y., Fu, S., Lin, Z., Hong, S., et al. (2020) Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma by Targeting the Epidermal Growth Factor Receptor Combined with Gemcitabine Plus Platinum. Cancer Management and Research, 12, 10353-10360. [Google Scholar] [CrossRef] [PubMed]
[18] Jin, T., Li, B. and Chen, X. (2014) A Phase II Trial of Endostar Combined with Gemcitabine and Cisplatin Chemotherapy in Patients with Metastatic Nasopharyngeal Carcinoma (NCT01612286). Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics, 21, 317-323. [Google Scholar] [CrossRef] [PubMed]
[19] Ruan, X., Liang, J., Pan, Y., Cai, R., Zhang, R.J., He, Z., et al. (2021) Apatinib for the Treatment of Metastatic or Locoregionally Recurrent Nasopharyngeal Carcinoma after Failure of Chemotherapy: A Multicenter, Single‐Arm, Prospective Phase 2 Study. Cancer, 127, 3163-3171. [Google Scholar] [CrossRef] [PubMed]
[20] Fang, Y., Su, N., Zou, Q., Cao, Y., Xia, Y., Tang, L., et al. (2023) Anlotinib as a Third-Line or Further Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Single-Arm, Phase 2 Clinical Trial. BMC Medicine, 21, Article No. 423. [Google Scholar] [CrossRef] [PubMed]
[21] You, R., Zou, X., Ding, X., Zhang, W., Zhang, M., Wang, X., et al. (2022) Gemcitabine Combined with Apatinib and Toripalimab in Recurrent or Metastatic Nasopharyngeal Carcinoma. Med, 3, 664-681.e6. [Google Scholar] [CrossRef] [PubMed]
[22] Jiang, Y., Fang, T., Lu, N., Bei, W., Dong, S., Xia, W., et al. (2023) Anti-PD1 Rechallenge in Combination with Anti-Angiogenesis or Anti-EGFR Treatment beyond Progression in Recurrent/Metastatic Nasopharyngeal Carcinoma Patients. Critical Reviews in Oncology/Hematology, 190, Article ID: 104113. [Google Scholar] [CrossRef] [PubMed]
[23] Zhang, M., Liu, T., You, R., Zou, X., Liu, Y., Ding, X., et al. (2022) Efficacy of Local Therapy to Metastatic Foci in Nasopharyngeal Carcinoma: Large-Cohort Strictly-Matched Retrospective Study. Therapeutic Advances in Medical Oncology, 14, 1-17. [Google Scholar] [CrossRef] [PubMed]
[24] Sun, X., Liang, Y., Liu, S., Chen, Q., Guo, S., Wen, Y., et al. (2019) Subdivision of Nasopharyngeal Carcinoma Patients with Bone-Only Metastasis at Diagnosis for Prediction of Survival and Treatment Guidance. Cancer Research and Treatment, 51, 1259-1268. [Google Scholar] [CrossRef] [PubMed]
[25] Lu, Y., Huang, H., Yang, H., Hu, X., Liu, M., Huang, C., et al. (2022) Maintenance Therapy Improves the Survival Outcomes of Patients with Metastatic Nasopharyngeal Carcinoma Responding to First-Line Chemotherapy: A Multicentre, Randomized Controlled Clinical Study. Journal of Cancer Research and Clinical Oncology, 149, 4327-4338. [Google Scholar] [CrossRef] [PubMed]
[26] Twu, C., Lin, P., Tsou, H., Liu, Y., Jiang, R., Liang, K., et al. (2022) Maintenance Metronomic Chemotherapy for Metastatic/Recurrent Nasopharyngeal Carcinoma. Head & Neck, 44, 1453-1461. [Google Scholar] [CrossRef] [PubMed]
[27] Guo, Q., Chen, M., Xu, H., Lu, T., Zhou, H., Chen, Y., et al. (2020) Oral Maintenance Chemotherapy Using S-1/Capecitabine in Metastatic Nasopharyngeal Carcinoma Patients after Systemic Chemotherapy: A Single-Institution Experience. Cancer Management and Research, 12, 1387-1396. [Google Scholar] [CrossRef] [PubMed]

为你推荐